about
Mechanism and significance of cell type-dependent neutralization of flavivirusesCastanospermine, a potent inhibitor of dengue virus infection in vitro and in vivoActively replicating West Nile virus is resistant to cytoplasmic delivery of siRNA.Zika in the Brain: New Models Shed Light on Viral InfectionMolecular Insight into Dengue Virus Pathogenesis and Its Implications for Disease ControlDegrees of maturity: the complex structure and biology of flavivirusesFlaviviruses: braking the enteringZika Virus Is Not Uniquely Stable at Physiological Temperatures Compared to Other FlavivirusesDevelopment of a highly protective combination monoclonal antibody therapy against Chikungunya virusN-Linked Glycosylation of West Nile Virus Envelope Proteins Influences Particle Assembly and InfectivityWest Nile Virus Discriminates between DC-SIGN and DC-SIGNR for Cellular Attachment and InfectionAntibody Recognition and Neutralization Determinants on Domains I and II of West Nile Virus Envelope ProteinInduction of Epitope-Specific Neutralizing Antibodies against West Nile VirusComplement Protein C1q Inhibits Antibody-Dependent Enhancement of Flavivirus Infection in an IgG Subclass-Specific MannerMaturation of West Nile Virus Modulates Sensitivity to Antibody-Mediated NeutralizationIdentification and Biochemical Characterization of Small-Molecule Inhibitors of West Nile Virus Serine Protease by a High-Throughput ScreenThe structural immunology of antibody protection against West Nile virusThe Stoichiometry of Antibody-Mediated Neutralization and Enhancement of West Nile Virus InfectionMolecular mechanisms of antibody-mediated neutralisation of flavivirus infectionStructural Insights into the Mechanisms of Antibody-Mediated Neutralization of Flavivirus Infection: Implications for Vaccine DevelopmentHuman Monoclonal Antibodies against West Nile Virus Induced by Natural Infection Neutralize at a Postattachment StepA West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical TrialComplement Protein C1q Reduces the Stoichiometric Threshold for Antibody-Mediated Neutralization of West Nile VirusProtonation of Individual Histidine Residues Is Not Required for the pH-Dependent Entry of West Nile Virus: Evaluation of the "Histidine Switch" HypothesisStructural Basis of Differential Neutralization of DENV-1 Genotypes by an Antibody that Recognizes a Cryptic EpitopeA dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virusAgo-2-mediated slicer activity is essential for anti-flaviviral efficacy of RNAi.Direct complement restriction of flavivirus infection requires glycan recognition by mannose-binding lectin.Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.A novel approach for the rapid mutagenesis and directed evolution of the structural genes of west nile virusCombined effects of the structural heterogeneity and dynamics of flaviviruses on antibody recognition.Rapid development of a DNA vaccine for Zika virusHuman antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assayA West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial.Opportunities and challenges in targeting HIV entry.Antibody-mediated neutralization of flaviviruses: a reductionist view.HIV-1 entry inhibitors: new targets, novel therapies.The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement.Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms.
P50
Q23032973-ADACE085-5D68-4DFE-A0B7-4E38FF99F507Q24531947-26C59066-E8D3-4041-A828-3AF3A38835B5Q24816212-9F9A985D-9DCC-4EA0-BA83-1914D08BF0C5Q26247174-0330DAD9-51F7-40A8-8ABD-9F3B0E7B6230Q26314452-9762C7F4-9142-4222-91D9-73630D8706F3Q26824712-310F31BC-8D8A-4C43-B209-7E6263143581Q26852435-F0DDA5B1-0EA7-46C1-B92D-908C8FD98E6DQ26970782-E949D87D-9DE2-431C-8C79-6F47047FBF5CQ27335008-CA93D4D1-1D05-4A13-B10E-1163AAC43BAAQ27472669-0DC20025-02B9-4B92-9375-9081480A04B5Q27472821-78FAA2DB-BFB4-43EE-A6DF-51DE22497998Q27477718-5B1D6BCE-3187-4359-9709-A57FC14469B9Q27484980-CE72B0AE-B442-4F16-91B2-AA50FD718D44Q27485131-0DCECBC9-D3A0-4E6B-8A26-08F18B0F39F0Q27485890-438E4598-C2CA-4C1F-84DF-60034E993E44Q27486814-5274F68E-5267-4D12-AAD0-2A30B0B11E81Q27487955-8BF632E8-4CC4-483C-BF2E-A65EA2C5E476Q27488224-72A9BCB7-C553-4419-A21F-889242A61CDBQ27488337-E64E7195-241F-49B1-8D76-2769AD60AA5CQ27488364-0022FF3A-AC52-43EF-B9C2-DB851D0D65CEQ27488791-8846E848-BE98-4F02-8826-C44F5D7AD2B9Q27488963-E8B6ABC4-68DA-42FB-BBDF-B6A94369FBB8Q27490423-2A7F55A8-740E-4CB0-8418-EF6079DB470BQ27490468-8C5715F3-E5F4-4E39-BCF7-153600075FD4Q27674417-C53E08DE-2108-4631-A02F-7874E036B0D9Q33954392-DE60B4E7-9CAD-48EC-AF0D-494C5498858DQ34079328-59A9B939-7B00-4F74-853A-B78689C725B0Q34089838-BF25315B-487B-4429-A9A3-5F6CC8ADFF9AQ34120070-DC17A201-1B80-4BB8-90AB-AEAE58D6833EQ34132718-98E8F61D-E9F2-41B4-A8DB-2A2A69426B0EQ34261496-AC2715F8-D043-48E9-A411-F3DAF8CE100EQ34542032-B283A1BF-EC61-4111-B38B-D2597CA95E05Q34609654-E75F3426-1DA5-4EB0-AF3A-519F5AE0C6CEQ34833926-902F4750-D2BF-44C0-8293-2E64A55D59C5Q34904992-380A506A-D9DB-4FCB-BCB1-5EAFDAF4ABD0Q34999617-73040C3D-6C65-4373-80B9-417B1F5A3A0FQ35044760-BF8C70CD-7720-49E5-871E-E1FA58F9ED1DQ35069160-CD5E1A65-A99B-407C-8EAF-E0282EFB6129Q35152094-A76A0987-721A-4F29-8E5A-A28AB07738E8Q35531167-5AD1A20F-2686-432B-AABE-056282762F2D
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-3795-4348
@en
name
Theodore C Pierson
@ast
Theodore C Pierson
@en
Theodore C Pierson
@nl
type
label
Theodore C Pierson
@ast
Theodore C Pierson
@en
Theodore C Pierson
@nl
prefLabel
Theodore C Pierson
@ast
Theodore C Pierson
@en
Theodore C Pierson
@nl
P106
P21
P31
P496
0000-0002-3795-4348